"Immunomodulation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Alteration of the immune system or of an immune response by agents that activate or suppress its function. This can include IMMUNIZATION or administration of immunomodulatory drugs. Immunomodulation can also encompass non-therapeutic alteration of the immune system effected by endogenous or exogenous substances.
- Immunomodulatory Therapy
- Immunomodulatory Therapies
- Therapies, Immunomodulatory
- Therapy, Immunomodulatory
Below are MeSH descriptors whose meaning is more general than "Immunomodulation".
Below are MeSH descriptors whose meaning is more specific than "Immunomodulation".
This graph shows the total number of publications written about "Immunomodulation" by people in this website by year, and whether "Immunomodulation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Immunomodulation" by people in Profiles.
Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis. Int Immunopharmacol. 2020 Aug; 85:106623.
PD-1+ melanocortin receptor dependent-Treg cells prevent autoimmune disease. Sci Rep. 2019 11 15; 9(1):16941.
Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 2019 09 18; 30(9):2247-2263.
Targets of immunomodulation in bacterial endophthalmitis. Prog Retin Eye Res. 2019 11; 73:100763.
Immunomodulatory response of layered small intestinal submucosa in a rat bladder regeneration model. J Biomed Mater Res B Appl Biomater. 2019 Aug; 107(6):1960-1969.
Unique, Intersecting, and Overlapping Roles of C/EBP ß and CREB in Cells of the Innate Immune System. Sci Rep. 2018 11 16; 8(1):16931.
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. Cancer Res. 2018 12 01; 78(23):6655-6665.
Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017 Mar - Apr; 41(2):125-128.
A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts. Clin Rev Allergy Immunol. 2016 Aug; 51(1):48-58.
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013 Jun; 123(6):2447-63.